Background: Two recent genome-wide association studies (GWAS) of pancreatic ductal adenocarcinoma (PDAC), conducted, respectively, in a Japanese and in a Chinese population, identified eight novel loci affecting PDAC risk.
Introduction
Pancreatic cancer mortality rates approach incidence rates (1) . Due to the lack of sufficient risk factors, finding genetic variants associated with disease risk is of utmost importance. A genome-wide association study (GWAS) performed in a Caucasian population identified 4 loci associated with pancreatic cancer risk; 2 more showed a strong association only in samples from prospective cohorts but not in retrospective case-control series (2, 3) . Two recent GWAS of pancreatic ductal adenocarcinoma (PDAC), conducted in Japan (4) and China (5), identified 8 novel loci affecting PDAC risk. We attempted to replicate these loci in a series of 1,299 PDAC and 2,884 healthy controls of European ancestry in the context of the PANcreatic Disease ReseArch (PANDoRA) consortium. We also attempted stratified analysis considering the different stages of the disease and addressed the possible involvement of the singlenucleotide polymorphisms (SNP) on the survival of patients.
Materials and Methods
Characteristics of the study population were described in detail elsewhere (6) . A total of 1,299 PDAC cases and 2,884 controls were used in this study. We genotyped 4 SNPs identified by Wu (5) and 3 identified by Low (4). Genotyping was conducted using the KASPar SNP genotyping system (KBiosciences; ref. 7) . Genotyping for British controls has been conducted in the context of a GWAS as described before (7) .
Risk analysis was conducted by logistic regression for multivariate analyses to assess the main effects of the genetic polymorphism on pancreatic cancer risk using the same inheritance model reported by Wu and Low. The most common allele in the controls was assigned as the reference category. Survival analysis was conducted using HRs and 95% confidence intervals (CI) in Cox proportional hazard models. All analyses were adjusted for age, gender, tumor-node-metastasis (TNM) stage (for survival only), and nationality. We also conducted stratified analysis for risk and survival considering the various nationalities and the different stages as different strata. All analyses were conducted with STATA software (StataCorp).
Results
The 7 SNPs were genotyped in all cases and healthy controls. Relevant characteristics of the study population are given in Table 1 . The average call rate was 95.86% (range, 93.93%-97.83%). Approximately 10% of the samples were analyzed in duplicate; the concordance rate of the genotypes was above 99%. The genotype distributions at all loci were in Hardy-Weinberg equilibrium in controls, with nonsignificant c 2 values (data not shown). The frequencies and distribution of the genotypes, the ORs and 95% CIs for the association with PDAC are shown in Table 2 . Heterozygous AG carriers of rs1547374 were associated with increased risk (OR, 1.16; 95% CI, 1.00-1.35; P ¼ 0.04), whereas we observed a trend for rs5768709 and decreased risk (P trend ¼ 0.04) and in heterozygous AG carriers of rs9502893 (OR, 0.84; 95% CI, 0.71-0.98; P ¼ 0.03). After Bonferroni correction, none of the above variants remained significant. Stratifying by nationality, we found that in the Polish subgroup, the G allele of rs372883 was significantly associated with increased risk (OR, 6.40; 95% CI, 2.28-17.91; P ¼ 0.0004). The sample size of the subgroup was rather small; there were 7 and 21 cases with AA or AG þ GG genotypes, respectively, and 43 and 80 Polish controls with either AA or AG þ GG genotypes. Therefore, this result has to be taken with caution. None of the other SNPs were significantly associated with PDAC risk, even when stratifying for tumor stage, or with patient survival, considering the correction for multiple testing. Finally, we observed no statistically significant association between the SNPs and survival when stratifying for nationality or tumor stage (Table 2) . Table 1 . 289 (243) 490 (406) 355 (227) 410 (442) 327 (176) 358 ( 
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Discussion and Conclusion
We previously replicated the majority of loci identified by the first GWAS on pancreatic cancer in a subset of the cases and controls used in the present study (7) . GWAS on PDAC risk in the Japanese (4) and Chinese population (5) yielded 3 new loci on chromosomes 6p25.3 (rs9502893, upstream of FOXQ1), 12p11.21 (rs708224, in the second intron of BICD1), and 7q36.2 (rs6464375, in the first intron of DPP6) and 5 novel susceptibility loci at chromosomes 21q21.3 (rs372883, in the BACH1 gene), 5p13.1 (rs2255280, in the DAB2 gene), 21q22.3 (rs1547374, upstream of TFF1 gene), 22q13.32 (rs5768709), and 10q26.11 (rs12413624). The last 2 SNPs are not located in the immediate vicinity of any gene. We attempted to validate 7 of the novel hits in an independent cohort of different ethnicity. We did not analyze rs2255280 because it is monomorphic in Caucasians (http://www.ncbi.nlm.nih.gov/projects/ SNP/snp_ref.cgi?rs ¼ 2255280). Such validation is necessary because attempts to generalize genetic associations across ethnicities have had mixed results. Also, the incidence of pancreatic cancer is substantially different among populations of distinct ancestry (5), possibly reflecting differences in genetic susceptibility. We had more than 95% statistical power to detect the reported associations; nevertheless, we observed none. Our results highlight the genetic differences across human populations and illustrate the importance of evaluating PDAC risk markers across ethnic groups.
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